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Background
The explosive increase in the number of people infected
with tuberculosis, multi drug resistant tuberculosis
(MDRTB), and injecting drug users (IDU) HIV/AIDS
has become a serious public health challenge in Russia.
The World Health Organization (WHO) is recommend-
ing policies including simultaneous use of highly active
antiretroviral therapy (HAART) to treat HIV/AIDS and
second line drugs to treat MDRTB. However, it is not
clear what would be the impact of implementing these
recommendations on tuberculosis and HIV/AIDS mor-
tality. In this context, the aim of this research is to
quantify the consequences of adopting these policies in
terms of deaths reduction.
Methods
A System Dynamics (SD) computer simulation model
was developed to represent the dynamic transmission of
tuberculosis, MDRTB, and HIV/AIDS. The model repre-
sented explicitly the complex interactions between these
diseases and how these link to their transmission and
spread in the population. The model simulated scenar-
ios, over a 20 years period, regarding MDRTB cure rate
and the fraction of HIV/AIDS patients covered by
HAART.
Results
The results over a 20 year period indicate that reduction
in tuberculosis and HIV associated tuberculosis deaths
would be negligible for HAART coverage up to 50%.
The reduction is only significant for HAART coverage
of 70% and above. Similarly, high MDRTB cure rate
reduces significantly deaths from tuberculosis and
MDRTB and this reduction is more important as the
HAART coverage is increased.
Discussion
This research demonstrates, through a computer simula-
tion model, that policies recommended by the WHO
will not be effective unless HAART coverage is ramped
up to include a sizeable fraction of HIV/AIDS patients.
This will have to be coupled with an extensive use of
second line drugs to address MDRTB. It is only through
combination of these policies that tuberculosis and
HIV/AIDS mortality could be reduced significantly.
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